- Home
- PHAR vs SEMR Comparison
PHAR vs SEMR Comparison
Compare PHAR & SEMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- SEMR
- Stock Information
- Founded
- PHAR 1988
- SEMR 2008
- Country
- PHAR Netherlands
- SEMR United States
- Employees
- PHAR N/A
- SEMR N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- SEMR EDP Services
- Sector
- PHAR Health Care
- SEMR Technology
- Exchange
- PHAR Nasdaq
- SEMR Nasdaq
- Market Cap
- PHAR 951.7M
- SEMR 1.1B
- IPO Year
- PHAR N/A
- SEMR 2021
- Fundamental
- Price
- PHAR $17.07
- SEMR $11.83
- Analyst Decision
- PHAR Strong Buy
- SEMR Buy
- Analyst Count
- PHAR 3
- SEMR 7
- Target Price
- PHAR $30.00
- SEMR $13.80
- AVG Volume (30 Days)
- PHAR 19.8K
- SEMR 4.5M
- Earning Date
- PHAR 11-06-2025
- SEMR 11-05-2025
- Dividend Yield
- PHAR N/A
- SEMR N/A
- EPS Growth
- PHAR N/A
- SEMR N/A
- EPS
- PHAR 0.00
- SEMR N/A
- Revenue
- PHAR $362,274,000.00
- SEMR $428,627,000.00
- Revenue This Year
- PHAR $17.70
- SEMR $20.28
- Revenue Next Year
- PHAR $12.25
- SEMR $16.41
- P/E Ratio
- PHAR $3,068.84
- SEMR N/A
- Revenue Growth
- PHAR 26.78
- SEMR 19.87
- 52 Week Low
- PHAR $7.35
- SEMR $6.56
- 52 Week High
- PHAR $17.76
- SEMR $18.74
- Technical
- Relative Strength Index (RSI)
- PHAR 60.37
- SEMR 81.28
- Support Level
- PHAR $15.81
- SEMR $6.58
- Resistance Level
- PHAR $17.50
- SEMR $11.83
- Average True Range (ATR)
- PHAR 0.91
- SEMR 0.31
- MACD
- PHAR 0.09
- SEMR 0.54
- Stochastic Oscillator
- PHAR 80.47
- SEMR 99.62
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.